Research programme: liposomal cancer therapies - MebiopharmAlternative Names: MBP-324; MBP-Y004; MBP-Y005; MBP-ZZZ
Latest Information Update: 27 Jun 2011
At a glance
- Originator Mebiopharm
- Mechanism of Action Alkylating agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 27 Jun 2011 Preclinical trials in Cancer in Japan are ongoing
- 10 May 2007 Preclinical trials in Cancer in Japan (unspecified route)